Image solutions provider iSchemaView has agreed to provide its RAPID imaging platform to help in selecting patients for the TIMELESS trial of tenecteplase drug to treat acute ischemic stroke (AIS).
Sponsored by Roche subsidiary Genentech, the trial is designed to assess the safety and efficacy of the drug in patients with late window AIS. The drug’s use will be evaluated for administration between 4.5 hours and 24 hours post stroke onset.
The RAPID neuroimaging platform is designed to deliver non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion images.
It consists of RAPID CTP for regions of abnormal cerebral hemodynamics, RAPID CTA to enable automatic visualisation of cerebral arteries, RAPID MRI for brain areas with low ADC values, and RAPID ASPECTS that offers automated scoring to evaluate early signs of brain ischemia.
Currently, the iSchemaView RAPID platform is being used in more than 300 stroke centres, approximately ten large-scale international trials and nearly 800 hospitals globally.
The company noted that the RAPID imaging solution had been used to select patients in early and late-window stroke trials such as SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND.
iSchemaView research vice-president Carolina Maier said: “RAPID is the only imaging technology for stroke that has been clinically validated, which is why it has been used in such a broad range of clinical trials and why it is used in over 1,000 stroke centers worldwide.”
Last month, the company secured the US Food and Drug Administration (FDA) clearance to use the RAPID neuroimaging platform for the selection of stroke patients who could benefit from endovascular thrombectomy (clot removal).